Eight therapies have outgrown the IPM growth and all therapies have double digit growths
The Indian pharma market (IPM) clocked Rs 7389 crores in March 2015 and has grown at 20.9 per cent. Amongst the top 10, Lupin grew by 32.4 per cent followed by Macleods at 31.7 per cent and Mankind at 28.7 per cent. 22 corporates have crossed the growth of IPM amongst the top 50 corporates. Amongst the top 50 corporates, Akumentis has the highest growth of 74 per cent followed by Wockhardt at 44 per cent and Allergan at 39.3 per cent. 46 corporates showed growths more than 10 per cent amongst the top 50 corporates.
Amongst the 11-20 ranked corporates, Aristo has the highest growth of 36.9 per cent followed by Sanofi at 30.8 per cent and Torrent at 30.5 per cent. Amongst the 40-50 ranked corporates, Allergan has the highest growth at 39.3 per cent followed by Apex at 19 per cent and Hetero at 18.2 per cent. Amongst the 51-60 ranked corporates, Eli Lilly grew at 40.3 per cent followed by Troikaa at 32.2 per cent and Systopic at 30.4 per cent. Amongst the 61-70 ranked corporates, Fresenius Kabi grew at 117.7 per cent followed by Boehringer which grew by 101 per cent followed by UCB at 36.1 per cent. GSK entered the Rs 3000-crore club as on MAT 2015.
Indian companies have grown at 21 per cent versus 20.9 per cent for MNCs in March 2015. Amongst the top 50 in MNCs, Allergan grew by 39.3 per cent followed by Sanofi at 30.8 per cent and Merck at 30.6 per cent. Under the non-NLEM category, Indian companies grew at 15.6 per cent whereas MNCs grew at 22.1 per cent.
The DPCO containing molecules market grew at 1.6 per cent whereas the non-DPCO market grew by 21.7 per cent and non-Sch Para 19 Market at 15.6 per cent resulting in an overall growth of 20.9 per cent for March 2015. The NLEM and non – NLEM category showed unit growth at 9.5 per cent and 13 per cent respectively. The non-Sch Para 19 Market grew at 13.2 per cent from units perspective. The DPCO 2013 portfolio for Pfizer grew at 25.6 per cent, Ranbaxy 27.6 per cent, GSK at 12.2 per cent and Abbott 15.5 per cent.
From therapy perspective, eight therapies have outgrown the IPM growth and all therapies have double digit growths. The respiratory market grew at 27.8 per cent, gastrointestinal market grew at 23.4 per cent, pain and analgesics market grew at 16.5 per cent whereas the anti-infectives grew at 22 per cent.
The anti-diabetic market grows at 32.9 per cent and cardiac at 19.1 per cent in chronic business. The derma market grows by 19.2 per cent and the urology market at 29.5 per cent. From regional perspective, 13 regions have outgrown the IPM growth. The UP East market grew the highest at 35.5 per cent followed by Tamil Nadu market at 29.7 per cent and North East Market at 28.9 per cent. No regions had negative growth in March 2015.
Amoxycillin + Clavulanic acid market grew at 27.9 per cent whereas Glimepiride + Metformin grew at 21.9 per cent at number two. The markets of paracetamol grew at 26.7 per cent, Atorvastatin 17.5 per cent, Probiotic Microbes at 21.3 per cent, Cefixime 28.7 per cent, Pantoprazole 17.7 per cent, Montelukast + Levocetrizine at 35 per cent, Glimepiride + Metformin + Pioglitazone at 26.7 per cent, Vitamin-D at 36.7 per cent, Hydroquinone + Mometasone + Tretinoin at 15.4 per cent, Voglibose + Metformin + Glimepiride at 65.7 per cent, Rosuvastatin at 24.7 per cent, Protein Supplements at 26.5 per cent.
Mixtard continues to lead the pack with Rs 36 crores for March 2015. Monocef grew at 60.2 per cent, Augmentin at 42.5 per cent, Glycomet-GP grew at 33.3 per cent, Mixtard at 28.7 per cent and Becosules at 24.1 per cent amongst the top 10 brands. Few Brands who have gained ranks include Pentaxim (+454), Electral Powder (+158), Januvia (+68), Janumet (+59), Spasmoproxyvon Plus (+53), Panderm Plus (+51), Monocef – O (+44), Shelcal (+41), Jalra-M (+36), Tonact (+24), Dolo (+10), Taxim (+9), amongst top 100 Brands over March 2014.
A total of 185 brands and 313 SKUs launched in March 2015. Top new brands for March were Variped, Yondelis and Ozurdex.
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.
For more information, visit http://www.aiocd.net